miRNA Blog http://mirnablog.com miRNA Research & Industry News Tue, 11 Apr 2017 03:34:47 +0000 en-US hourly 1 http://mirnablog.com/wp-content/uploads/cropped-Logo-NEW-square-hd-600-150x150.png miRNA Blog http://mirnablog.com 32 32 The UEA small RNA Workbench Version 4.4 http://mirnablog.com/the-uea-small-rna-workbench-version-4-4/ http://mirnablog.com/the-uea-small-rna-workbench-version-4-4/#respond Sat, 08 Apr 2017 17:55:36 +0000 http://miRNAblog.com/?p=2703

A suite of tools for analyzing micro RNA and other small RNA data from High-Throughput Sequencing devices

UEA sRNA workbenchThis release is the next Alpha test for the latest version of the UEA small RNA workbench, Version 4.0 (check the frequently encountered problems for a list of known issues).

This version is released as java binaries only to streamline the release process until the software moves into the stable release stage of its lifecycle.

The authors highly recommend using the latest version of Java to run this build. Anything past update release 111 of the JDK/JRE is well advised due to fixes made to the javascript portion of JavaFX.

This release is only available as an ON DISK mode build.

NEW: Filter 2

A new version of the filter tool is now available as part of a pre-configured workflow (currently the workflow is on its own, new workflows will be available soon with the filter tool included).

The Filter 2 program retains all of the functionality of the original tool with the added ability to update the RFAM database files. The original Filter program used an old version of the t/rRNA database taken from the original srna tools programs. The updated database is likely to be much larger and therefore will add to the processing time.


small RNA workbench website


http://mirnablog.com/the-uea-small-rna-workbench-version-4-4/feed/ 0
miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides http://mirnablog.com/miragen-therapeutics-receives-orphan-drug-designation-for-mrg-106-for-the-treatment-of-mycosis-fungoides/ http://mirnablog.com/miragen-therapeutics-receives-orphan-drug-designation-for-mrg-106-for-the-treatment-of-mycosis-fungoides/#respond Tue, 04 Apr 2017 02:50:05 +0000 http://miRNAblog.com/?p=2700 miRagen Therapeutics logoBOULDER, Colo., March 31, 2017 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan-drug designation to miRagen’s product candidate, MRG-106, for the treatment of mycosis fungoides. Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma (“CTCL”). CTCL occurs when certain types of T-cells become cancerous and cause debilitating tumors in the skin and in other parts of the body.

Paul Rubin, M.D., miRagen’s Executive Vice President of Research and Development, said, “We see the FDA’s granting of orphan-drug designation for MRG-106 as underscoring the medical need for novel therapies in the treatment of mycosis fungoides, and we believe it should facilitate our ability to continue developing this product candidate for potential use in these patients.”

“This designation is an important step forward for our MRG-106 program as we continue to advance our clinical and regulatory strategy in areas of high unmet medical need,” added William S. Marshall, Ph.D., President and CEO of miRagen. “Patients suffering from mycosis fungoides have few treatment options available, and MRG-106 could be an alternative approach to battling the disease.”

About Miragen Therapeutics, Inc.

Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. microRNAs are short RNA molecules, or oligonucleotides, that regulate gene expression or activity and play a vital role in influencing the pathways responsible for many disease processes. miRagen believes its experience in microRNA biology and chemistry, drug discovery, bioinformatics, and translational medicine provide it with a potential competitive advantage to identify and develop microRNA-targeted drugs designed to regulate gene pathways to result in disease modification. miRagen uses its expertise in systems biology and oligonucleotide chemistry to discover and develop a pipeline of product candidates. miRagen’s two lead product candidates, MRG-106 and MRG-201, are currently in Phase 1 clinical trials. miRagen’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis. In addition to miRagen’s clinical programs, it continues to discover and develop a pipeline of pre-clinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first in human studies once it has established the pharmacokinetics (the movement of drug into, through, and out of the body), pharmacodynamics (the effect and mechanism of action of a drug), safety and manufacturability of the product candidate in preclinical studies.  For more information, please visit www.miragentherapeutics.com.

For information on clinical trials please visit www.clinicaltrials.gov.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, including statements regarding miRagen’s strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation: that miRagen has incurred losses since its inception, has a limited operating history on which to assess its business, and anticipates that it will continue to incur significant losses for the foreseeable future; miRagen has never generated any revenue from product sales and may never be profitable; raising additional capital may cause dilution to miRagen’s stockholders, restrict its operations or require it to relinquish rights; miRagen may be unsuccessful in maintaining orphan-drug designation for its product candidates because even after an orphan drug is approved, the FDA can subsequently approve a different drug for the same indication if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care; clinical trials are costly, time consuming and inherently risky, and miRagen may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; the approach it is taking to discover and develop novel therapeutics using microRNA is unproven and may never lead to marketable products; miRagen’s microRNA therapeutic product candidates are based on a relatively novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all; to date, no microRNA therapeutics have been approved for marketing in the United States; miRagen may not be able to develop or identify technology that can effectively deliver MRG-106, MRG-201 or any other of miRagen’s microRNA-targeted product candidates to the intended diseased cells or tissues, and any failure in such delivery technology could adversely affect and delay the development of MRG-106, MRG-201 and miRagen’s other product candidates; and miRagen’s product candidates may cause undesirable side effects or have other properties that could delay or prevent the regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.

miRagen has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in under the heading “Risk Factors” in miRagen’s Annual Report on Form 10-K and any subsequent periodic reports filed with the Securities and Exchange Commission. Moreover, miRagen operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. miRagen undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. 

Source: Miragen Therapeutics, Inc.

http://mirnablog.com/miragen-therapeutics-receives-orphan-drug-designation-for-mrg-106-for-the-treatment-of-mycosis-fungoides/feed/ 0
MicroRNA Treatment Restores Nerve Insulation, Limb Function in Mice with MS http://mirnablog.com/microrna-treatment-restores-nerve-insulation-limb-function-in-mice-with-ms/ http://mirnablog.com/microrna-treatment-restores-nerve-insulation-limb-function-in-mice-with-ms/#respond Mon, 27 Mar 2017 17:23:25 +0000 http://mirnablog.com/?p=2690 Study Sheds Light on Possible Therapeutic Approach for Neurodegenerative Disease

Cincinnati Children's Hospital Logo

CINCINNATI, March 27, 2017 /PRNewswire-USNewswire/ — Scientists partially re-insulated ravaged nerves in mouse models of multiple sclerosis (MS) and restored limb mobility by treating the animals with a small non-coding RNA called a microRNA.

In a study published online March 27 in Developmental Cell, researchers at Cincinnati Children’s Hospital Medical Center report that treatment with a microRNA called miR-219 restarted production of a substance called myelin in nerves of the central nervous system. Myelin forms a protective sheath around nerves, allowing them to efficiently transmit electrical impulses that stimulate movement.

Study authors administered miR-219 into the spinal columns and cerebrospinal fluid of mice with nerve coatings damaged by a chemical called lysolecithin or by autoimmune encephalomyelitis induced in the animals, which is used to model MS. Treatment with miR-219 reinvigorated the function of damaged cells called oligodendrocytes that produce myelin, which allowed the substance to reform and reinsulate nerves.

“We show that miR-219 targets multiple processes that inhibit myelin formation after nerve injury by the disease process, and that treatment with this microRNA partially restores myelination and limb function,” said Q. Richard Lu, PhD, lead investigator and scientific director of the Brain Tumor Center at Cincinnati Children’s. “It is conceivable that augmenting miR-219 treatment with other blockers of myelin regrowth may provide a multipoint treatment strategy for people with demyelinating diseases like MS.”

The authors stress that because their study was conducted in laboratory mouse models of disease, their data cannot at this stage be applied to clinical treatment in humans.

Lu’s laboratory studies how certain glial cell subtypes of the central and peripheral nervous system form, participate in regeneration and how they can transform into cancerous cells.

Molecular Silencer

MicroRNAs are short segments of RNA encoded on the chromosomes of cells. They regulate gene expression in cells by acting as molecular silencers, essentially blocking gene expression in certain situations.

This image shows restored presence of proteins indicating myelin reformation (shown in red) in the lumbar spinal cord of a mouse treated with miR-219 mimic after injury to its central nervous system.


A number of earlier research papers have pointed to the absence of miR-219 in the damaged nerves and tissues with certain neurodegenerative diseases like multiple sclerosis.

Lu and his colleagues tested the presence and effects of miR-219 in genetically-engineered mouse models of MS with chemically induced nerve coating damage by lysolecithin and autoimmune encephalomyelitis. They also deleted miR-219 in mice to test the impact this had on myelin-forming oligodendrocyte cells.

The absence of miR-219 allowed a surge of activity by several inhibitors of nerve re-myelination – including a protein called Lingo1. Further testing revealed that miR-219 is an essential part of a network that targets and blocks molecules that inhibit the ability of oligodendrocytes to form myelin.

This prompted the researchers to test treatment with miR-219 in their animal models. For this they used a miR-219 mimic – essentially a synthesized version of the microRNA. After administering the mimic to their mouse models, the researchers noted improved limb function and regeneration of the myelin coating on nerves.

Next steps

Lu and his colleagues are now trying to develop additional mimics of miR-219 and therapeutically effective formulations of the microRNA to ease its delivery – particularly into brain tissue. The researchers also continue to test the potential effectiveness of miR-219 treatment in different models of neurodegenerative disease.

Funding for the research came in part from grants from the National Institutes of Health (R01NS072427, R01NS075243, R01NS065808, R21NS087474) and the National Multiple Sclerosis Society (NMSS-4727, RG 4172-A-4).


SOURCE Cincinnati Children’s Hospital Medical Center

CONTACT: Nick Miller, 513-803-6035, nicholas.miller@cchmc.org


http://mirnablog.com/microrna-treatment-restores-nerve-insulation-limb-function-in-mice-with-ms/feed/ 0
Call for Papers: Special Issue “Non Coding RNA Methods” http://mirnablog.com/call-for-papers-special-issue-non-coding-rna-methods/ http://mirnablog.com/call-for-papers-special-issue-non-coding-rna-methods/#respond Sun, 26 Mar 2017 20:46:24 +0000 http://mirnablog.com/?p=2687 Deadline for manuscript submissions: 30 April 2017

Non-coding RNA is still accepting submissions for a Special Issue on Non Coding RNA methods. This Special Issue is co guest-edited by Dr. Piero Carninci from the RIKEN Center for Life Science Technologies in Japan and Dr. Florent Hubé from the National Center for Scientific Research (CNRS) in Paris. Accepted papers are published online immediately after copy editing. Non-Coding RNA is an Open Access journal.

ncRNA is a rapidly growing field in which new research methods are continuously appearing.  With this Special Issue, the editors aim to collect a selection of articles on newly developed techniques of special interest for researchers in the ncRNA field.

Considered will be manuscripts that report on new experimental methods , as well as reviews of exceptional interest that focus on newly developed techniques for ncRNA research that include:

  • ncRNA analysis programs
  • ncRNA Chromatography methods
  • ncRNA structure analysis
  • ncRNA function analysis
  • ncRNA by high-throughput screening
  • ncRNA Database/Annotation
  • ncRNA imaging
  • methods to detect the interactome of RNA (with proteins, with chromatin, etc.)

Dr. Piero Carninci
Dr. Florent Hubé
Guest Editors

Please use the online submission system and indicate in your cover letter that you would like to have your manuscript considered for the Special Issue “Non Coding RNA methods”. If you would like to enquire about the suitability of your article for this Special Issue, please email your pre-submission enquiry to Dr. Piero Carninci  carninci@riken.jp or to Dr. Florent Hubé florent.hube@univ-paris-diderot.fr with the ncRNA Editorial Office ncRNA@mdpi.com in copy.


Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

http://mirnablog.com/call-for-papers-special-issue-non-coding-rna-methods/feed/ 0
Upcoming Webinar: Analyzing RNA-seq Data http://mirnablog.com/upcoming-webinar-analyzing-rna-seq-data/ http://mirnablog.com/upcoming-webinar-analyzing-rna-seq-data/#respond Sat, 25 Mar 2017 19:48:50 +0000 http://mirnablog.com/?p=2683 qlucore-rna-seq-data-analysis.pngMarch 28th 2017:
Demonstration of Qlucore Omics Explorer, the bioinformatics software for scientists, biologists looking for a user-friendly analysis software for instant visualization and exploration of data.

Sign up now at www.qlucore.com/webinar .
Registration on the site will allow you to watch previously recorded webinars as well.

To book a Personalized webinar, please e-mail qlucoreinfo@qlucore.com.

http://mirnablog.com/upcoming-webinar-analyzing-rna-seq-data/feed/ 0
Conference: Non-Coding RNAs and Epigenetics in Cancer http://mirnablog.com/conference-non-coding-rnas-and-epigenetics-in-cancer/ http://mirnablog.com/conference-non-coding-rnas-and-epigenetics-in-cancer/#respond Fri, 24 Mar 2017 15:18:15 +0000 http://mirnablog.com/?p=2676 2nd International Symposium on Frontiers in Molecular Science

Non-Coding RNAs & Epigenetics in Cancer


2nd International Symposium on Frontiers in Molecular Science Non-Coding RNAs and Epigenetics in Cancer logo

21–23 June 2017

Biocenter, University of Basel, Basel, Switzerland

Announcement: Final Deadline for Early Registration Fees 31 March 2017

An international scientific conference organized by the MDPI journals International Journal of Molecular Sciences and Non-Coding RNA

One of the most unexpected and fascinating discoveries in oncology over the past decade has been the interplay between abnormalities in protein-coding genes and non-coding RNAs (ncRNAs), which are causally involved in cancer initiation, progression, and dissemination. Although, to date, the most studied non-coding RNAs (ncRNAs) are miRNAs, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. At the conference, entitled “Non-Coding RNAs and Epigenetics in Cancer”, leaders in the field will present the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges. We hope to see you all, young in spirit and mind, in the new Eldorado of Science topics in biomedical sciences!

The Non-Coding RNAs and Epigenetics in Cancer will be held in Basel, Switzerland, from 21st to 23rd of June 2017. It will comprise five plenary sessions to highlight the most exciting developments and the latest breakthroughs in oncology.

If you are interested in participating in this conference, and in presenting a poster, or in being selected for a short talk, please register and get in touch with the conference secretariat. The program of the conference is being assembled and will be fully available by March 2017.

For more details and to register: http://sciforum.net/conference/ncRNA-Cancer

http://mirnablog.com/conference-non-coding-rnas-and-epigenetics-in-cancer/feed/ 0
RNAMEDICINE 2017 Symposium http://mirnablog.com/rnamedicine-2017-symposium/ http://mirnablog.com/rnamedicine-2017-symposium/#respond Fri, 24 Mar 2017 05:00:49 +0000 http://mirnablog.com/?p=2671 RNAMEDICINE 2017

RNA MEDICINE 2017 conference Boston

The third annual day-long iRM (Institute for RNA Medicine – BIDMC Cancer Center/Harvard Medical School) symposium will be held Thursday April 27, 2017, at the Joseph B. Martin Conference Center at Harvard Medical School in Boston. Registration is open!

http://mirnablog.com/rnamedicine-2017-symposium/feed/ 0
REVIEW – MicroRNA therapeutics: towards a new era for the management of cancer and other diseases http://mirnablog.com/review-microrna-therapeutics-towards-a-new-era-for-the-management-of-cancer-and-other-diseases/ http://mirnablog.com/review-microrna-therapeutics-towards-a-new-era-for-the-management-of-cancer-and-other-diseases/#respond Thu, 23 Mar 2017 04:49:38 +0000 http://mirnablog.com/?p=2658
New Nature Reviews Drug Discovery publication in the Series “RNA-based therapies”:

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

Summary of the key steps in the development of miRNA therapeutics.Abstract: In just over two decades since the discovery of the first microRNA (miRNA), the field of miRNA biology has expanded considerably. Insights into the roles of miRNAs in development and disease, particularly in cancer, have made miRNAs attractive tools and targets for novel therapeutic approaches. Functional studies have confirmed that miRNA dysregulation is causal in many cases of cancer, with miRNAs acting as tumour suppressors or oncogenes (oncomiRs), and miRNA mimics and molecules targeted at miRNAs (antimiRs) have shown promise in preclinical development. Several miRNA-targeted therapeutics have reached clinical development, including a mimic of the tumour suppressor miRNA miR-34, which reached phase I clinical trials for treating cancer, and antimiRs targeted at miR-122, which reached phase II trials for treating hepatitis. In this article, we describe recent advances in our understanding of miRNAs in cancer and in other diseases and provide an overview of current miRNA therapeutics in the clinic. The authors also discuss the challenge of identifying the most efficacious therapeutic candidates and provide a perspective on achieving safe and targeted delivery of miRNA therapeutics.

Rupaimoole R, Slack FJ.
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017 Mar;16(3):203-222.
doi: 10.1038/nrd.2016.246. Review. PubMed PMID: 28209991.

Full article: http://www.nature.com/nrd/journal/v16/n3/full/nrd.2016.246.html


http://mirnablog.com/review-microrna-therapeutics-towards-a-new-era-for-the-management-of-cancer-and-other-diseases/feed/ 0
Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017 http://mirnablog.com/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017/ http://mirnablog.com/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017/#respond Wed, 15 Mar 2017 05:18:48 +0000 http://mirnablog.com/?p=2646 Indrani Das of New Jersey Wins $250,000 Top Award with microRNA-124a related research.

Forty Finalists From Across U.S. Take Home More Than $1.8 Million inNation’s Oldest and Most Prestigious High School Science and Mathematics Competition


WASHINGTON, March 14, 2017 /PRNewswire-USNewswire/ — Society for Science & the Public and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that Indrani Das, 17, of Oradell, New Jersey, won the top award in the Regeneron Science Talent Search, the nation’s oldest and most prestigious science and math competition. Forty finalists, including Indrani, were honored tonight at the annual Regeneron Science Talent Search Awards Gala for their research projects demonstrating exceptional scientific and mathematical ability, taking home more than $1.8 million in awards provided by Regeneron.

Regeneron Science Talent Search Winners 2017

Washington, D.C., March 14, 2017-Indrani Das, 17, of Oradell, New Jersey, wins top prize and $250,000 in Regeneron Science Talent Search, founded and produced by Society for Science & the Public.


Indrani Das, 17, of Oradell, New Jersey, won the top award of $250,000 for her study of a possible approach to treating the death of neurons due to brain injury or neurodegenerative disease. A contributor to neuron death is astrogliosis, a condition that occurs when cells called astrocytes react to injury by growing, dividing and reducing their uptake of glutamate, which in excess is toxic to neurons. In a laboratory model, she showed that exosomes isolated from astrocytes transfected with microRNA-124a both improved astrocyte uptake of glutamate and increased neuron survival. Indrani mentors younger researchers and tutors math in addition to playing the piccolo trumpet in a four-person jazz ensemble.

Second place honors and $175,000 went to Aaron Yeiser, 18, of Schwenksville, Pennsylvania, for his development of a new mathematical method for solving partial differential equations on complicated geometries. Partial differential equations are ubiquitous in science and engineering and are currently solved using computers. He developed a more efficient way to do this and applied it to the challenging field of computational fluid dynamics. Aaron is a distance runner who competes in cross country and track. During the summer, he teaches sailing in Maine.

Third place honors and $150,000 went to Arjun Ramani, 18, of West Lafayette, Indiana, for blending the mathematical field of graph theory with computer programming to answer questions about networks.  Typically, these questions require statistical comparisons to hundreds or thousands of random graphs, a process that can take a relatively long time. He developed an algorithm that greatly accelerated the process by reducing the time required to generate these graphs. Arjun is an award-winning debater and accomplished tennis player and coach, and also volunteers at a local science museum.

This year, Regeneron became only the third sponsor of the Science Talent Search, following previous sponsors Westinghouse and Intel. As part of its 10-year, $100 million commitment, Regeneron significantly increased awards to better reward the nation’s brightest young scientists and encourage their continued pursuit of scientific innovation. In total, this year’s finalists received over $1.8 million in awards provided by Regeneron, which distributed $3.1 million in awards overall to Regeneron Science Talent Search 2017 finalists, scholars and their schools. Regeneron is also supporting efforts to increase nationwide student and school participation in the Science Talent Search.

Society for Science and the Public Logo“Now more than ever, we need our nation’s best and brightest young minds to pursue their interest in science and use their talents to solve our world’s most intractable problems,” said Maya Ajmera, President and CEO of Society for Science & the Public and Publisher of Science News. “I congratulate our finalists, who are all poised to become our future scientific leaders.” Society for Science & the Public has organized and produced the Science Talent Search since it was founded in 1942.

“Congratulations to the Regeneron Science Talent Search 2017 top winners,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. “My experience as a Science Talent Search winner led me to embark on a career in science, and I hope it will inspire these exceptional young scientists to become the next generation of innovators that will improve the world and solve some of our most pressing challenges as a society.”

Other top honors from the competition include:

Fourth Place: Byron Xu, 17, of Sugar Land, Texas, received a $100,000 award for his examination of marine seismic data – the reflections of sound waves – with the goal of calculating ocean water temperatures in more detail than current techniques allow.

Fifth Place: Archana Verma, 17, of Jericho, New York, received a $90,000 award for her study of the molecular orbital energy dynamics of dyes, which may someday result in windows that produce solar energy.

Sixth Place: Laura Pierson, 17, of Oakland, California, received an $80,000 award for her use of theoretical algebra to study the representation theory of mathematically symmetric groups.

Seventh Place: Prathik Naidu, 18, of Potomac Falls, Virginia, received a $70,000 award for his creation of a new machine learning software to study 3-D interactions of the human genome in cancer.

Eighth Place: Ethan Novek, 18, of Greenwich, Connecticut, received a $60,000 award for his development of a new carbon capture process powered entirely by abundant low-temperature waste heat.

Ninth Place: Vrinda Madan, 17, of Orlando, Florida, received a $50,000 award for her study of 24 potential compounds for the treatment of malaria, in which she found two potential candidates that appear to target the disease-causing organism in a novel way and may warrant further study.

Tenth Place: Stefan Wan, 17, of Wellington, Florida, received a $40,000 award for his development of a new material to remove phosphate from wastewater and storm runoff and then recycle it to enrich farm soil.

The remaining 30 finalists each received $25,000.

Of more than 1,700 high school seniors who entered the Regeneron Science Talent Search 2017, roughly 300 were named scholars in January. Of those scholars, 40 students were named finalists and invited to Washington, D.C. to compete for the top 10 awards, meet with national leaders and share their projects with the public at the National Geographic Society. These students join the ranks of other Science Talent Search alumni who have gone on to receive more than 100 of the world’s most esteemed science and math honors, including the Nobel Prize and the National Medal of Science.

About the Regeneron Science Talent Search
The Regeneron Science Talent Search, a program of Society for Science & the Public since 1942, is the nation’s oldest and most prestigious science and math competition for high school seniors. Each year, approximately 1,700 student entrants to the Science Talent Search submit original research in critically important scientific fields of study and are judged by leading experts in their fields. Unique among high school competitions in the U.S. and globally, the Regeneron Science Talent Search focuses on identifying the next generation of scientists and engineers who will provide critical leadership in solving some of the world’s most pressing challenges while shaping the future of research and development for our nation and the world.

As part of its 10-year, $100 million commitment, Regeneron has significantly increased awards to better reward the best and brightest young talent and encourage their continued pursuit of scientific innovation. Regeneron has nearly doubled the overall award distribution to $3.1 million annually, and increased the top award to $250,000. As a key component of the Regeneron sponsorship, $30 million will be dedicated to supporting initiatives focused on increasing outreach and equity for students across the United States to nurture their interest in the sciences. This funding will support programming designed to reach new and underprivileged communities, support teachers and inspire more students to pursue science research and STEM careers.

Program alumni include recipients of the world’s most coveted science and math honors, including eleven National Medals of Science, four Breakthrough Prizes, eighteen MacArthur Foundation Fellowships, two Fields Medals and twelve Nobel Prizes. Distinguished Science Talent Search alumni include Society Trustees Mary Sue Coleman (president emeritus, University of Michigan), Tom Leighton (co-founder and CEO, Akamai Technologies), Paul Maddon (founder of Progenics) and Frank Wilczek (2004 Nobel Prize in Physics), among many others.

Intel was the title sponsor of the Science Talent Search from 1998-2016. For the first 55 years (1942-1997) of the Science Talent Search, Westinghouse was the title sponsor.

Learn more at https://student.societyforscience.org/regeneron-sts and https://medium.com/regeneron-science-talent-search.

About Society for Science & the Public
Society for Science & the Public is dedicated to the achievement of young scientists in independent research and to public engagement in science. Established in 1921, Society is a nonprofit whose vision is to promote the understanding and appreciation of science and the vital role it plays in human advancement. Through its world-class competitions, including the Regeneron Science Talent Search, the Intel International Science and Engineering Fair, and the Broadcom MASTERS, and its award-winning magazine, Science News and Science News for Students, Society for Science & the Public is committed to inform, educate, and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

SOURCE Society for Science & the Public

http://mirnablog.com/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017/feed/ 0